- ASSISTANT PROFESSOR Medicine, Gastroenterology
- Angiodysplasia Of The Colon
- Antibiotic-Associated Colitis-C Difficile
- Barrett's Esophagus
- Celiac Disease
- Chronic Pancreatitis
- Colon Polypectomy
- Colon Polyps
- Colorectal Cancer
- Crohn's Disease
- Enteral Feeding
- Esophageal Cancer
- Familial Adenomatous Polyposis
- Flexible Sigmoidoscopy
- Inflammatory Bowel Disease
- Iron-Deficiency Anemia
- Irritable Bowel Syndrome
- Pancreatic Cancer
- Peptic Ulcer
- Percutaneous Endoscopic Gastrostomy
- Rectal Cancer
- Short Bowel Syndrome
- Stomach Cancer
- Ulcerative Colitis
- Upper GI Endoscopy
MBBS, University College of Medical Sciences
Residency, Internal Medicine
Mount Sinai Hospital
Dr Mehandru straddles the world of clinical care and laboratory based investigation. He graduated with honors from the University College of Medical Sciences, Delhi University, India. He then completed residency training in Internal Medicine at the NYU School of Medicine where he also served as Medical Chief Resident. He received subspecialty training in Clinical Gastroenterology at The Icahn School of Medicine at Mount Sinai.
Dr Mehandru undertook post-doctoral training at the Rockefeller University, first working in the Laboratory of Dr. David Ho (with Dr. Martin Markowitz) and then in the Laboratory of Dr. Ralph Steinman, Nobel Laureate in Physiology or Medicine (2011).
During this period, Dr. Mehandru, reported on the preferential depletion of gut lymphocytes during acute HIV-1 infection and on the lack of immune reconstitution in the GI tract following years of apparently suppressive antiretroviral therapy.
After finishing his post-doctoral training, Dr. Mehandru was invited to join the faculty at Mount Sinai where in addition to serving as an Assistant Professor of Gastroenterology, he leads a laboratory of Mucosal Immunology since 2013. Dr. Mehandru’s research interests include mucosal trafficking, the host-pathogen interface, dendritic cell biology and mucosal immunopathology in primary and acquired immunodeficiency states. He is an NIH-funded investigator who has received multiple awards listed below.
Lee H, Ruane D, Law K, Ho Y, Garg A, Rahman A, Esterházy D, Cheong C, Goljo E, Sikora AG, Mucida D, Chen BK, Govindraj S, Breton G, Mehandru S. Phenotype and function of nasal dendritic cells. Mucosal immunology 2015 Feb;.
Anandasabapathy N, Feder R, Mollah S, Tse SW, Longhi MP, Mehandru S, Matos I, Cheong C, Ruane D, Brane L, Teixeira A, Dobrin J, Mizenina O, Park CG, Meredith M, Clausen BE, Nussenzweig MC, Steinman RM. Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. The Journal of experimental medicine 2014 Aug; 211(9).
Ruel J, Ruane D, Mehandru S, Gower-Rousseau C, Colombel JF. IBD across the age spectrum: is it the same disease?. Nature reviews. Gastroenterology & hepatology 2014 Feb; 11(2).
Ruane D, Brane L, Reis BS, Cheong C, Poles J, Do Y, Zhu H, Velinzon K, Choi JH, Studt N, Mayer L, Lavelle EC, Steinman RM, Mucida D, Mehandru S. Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract. The Journal of experimental medicine 2013 Aug; 210(9).
Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, Mohri H, Markowitz M. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS pathogens 2012 Feb; 8(2).
Choi JH, Cheong C, Dandamudi DB, Park CG, Rodriguez A, Mehandru S, Velinzon K, Jung IH, Yoo JY, Oh GT, Steinman RM. Flt3 signaling-dependent dendritic cells protect against atherosclerosis. Immunity 2011 Nov; 35(5).
Mehandru S, Dandekar S. Role of the gastrointestinal tract in establishing infection in primates and humans. Current opinion in HIV and AIDS 2008 Jan; 3(1).
Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, Boden D, Galovich J, Tenner-Racz K, Racz P, Carrington M, Petropoulos C, Katinger H, Markowitz M. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. Journal of virology 2007 Oct; 81(20).
Mehandru S, Poles MA, Tenner-Racz K, Jean-Pierre P, Manuelli V, Lopez P, Shet A, Low A, Mohri H, Boden D, Racz P, Markowitz M. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS medicine 2006 Dec; 3(12).
Mehandru S, Poles MA, Tenner-Racz K, Manuelli V, Jean-Pierre P, Lopez P, Shet A, Low A, Mohri H, Boden D, Racz P, Markowitz M. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. Journal of virology 2007 Jan; 81(2).
Bini EJ, Mehandru S. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Alimentary pharmacology & therapeutics 2006 Mar; 23(6).
Mehandru S, Tenner-Racz K, Racz P, Markowitz M. The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection. The Journal of allergy and clinical immunology 2005 Aug; 116(2).
Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, Kim A, Chung C, Jean-Pierre P, Horowitz A, La Mar M, Wrin T, Parkin N, Poles M, Petropoulos C, Mullen M, Boden D, Ho DD. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet; 365(9464).
Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, Hogan C, Vasan S, Katinger H, Petropoulos CJ, Markowitz M. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. Journal of virology 2004 Dec; 78(24).
Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Archives of internal medicine 2004 Nov; 164(21).
Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. The Journal of experimental medicine 2004 Sep; 200(6).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Mehandru has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
31-60 21St Street
Long Island City, NY 11106
- Thursday 2:00am - 5:00am
- Accepts MOST insurances
- Aetna HMO
- Aetna PPO
- BCBS HMO